by The global artificial intelligence (AI) in oncology market size accounted for US$ 891.44 Mn in 2022 and is projected to reach around USD 10,680.29 Mn by 2032, growing at a CAGR of 28.18% from 2023 to 2032.
Report Summary
The global artificial intelligence (AI) in oncology market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the artificial intelligence (AI) in oncology market across the globe.
A comprehensive estimate on the artificial intelligence (AI) in oncology market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of artificial intelligence (AI) in oncology during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@https://www.precedenceresearch.com/sample/2638
Artificial Intelligence (AI) in Oncology Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 1,142.72 Million |
| Market Size by 2032 | USD 10,680.29 Million |
| Growth Rate from 2023 to 2032 | CAGR of 28.18% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Component, By Cancer Type, By Treatment Type and By End-Users |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized artificial intelligence (AI) in oncology market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Immunohistochemistry Market Size To Cross USD 4.5 Bn By 2032
Artificial Intelligence (AI) in Oncology Market Players
The report includes the profiles of key artificial intelligence (AI) in oncology market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- IBM
- Azra AI
- Siemens Healthineers
- GE Healthcare
- Intel
- Path AI
- NVIDIA
- Concert.AI
- Digital Diagnostics Inc.
- Median Technologies
Market Segmentation
By Component
- Software Solutions
- Hardware
- Services
By Cancer Type
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Brain Tumor
- Others
By Treatment Type
- Chemotherapy
- Radiotherapy
- Immunotherapy
- Others
By End-Users
- Hospitals
- Diagnostic Centers
- Pharmaceutical Companies
- Research Institutes
- Others
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Artificial Intelligence (AI) in Oncology Market
5.1. COVID-19 Landscape: Artificial Intelligence (AI) in Oncology Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Artificial Intelligence (AI) in Oncology Market, By Component
8.1. Artificial Intelligence (AI) in Oncology Market, by Component, 2023-2032
8.1.1. Software Solutions
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Hardware
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Artificial Intelligence (AI) in Oncology Market, By Cancer Type
9.1. Artificial Intelligence (AI) in Oncology Market, by Cancer Type, 2023-2032
9.1.1. Breast Cancer
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Prostate Cancer
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Colorectal Cancer
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Brain Tumor
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Artificial Intelligence (AI) in Oncology Market, By Treatment Type
10.1. Artificial Intelligence (AI) in Oncology Market, by Treatment Type, 2023-2032
10.1.1. Chemotherapy
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Radiotherapy
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Immunotherapy
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Artificial Intelligence (AI) in Oncology Market, By End-Users
11.1. Artificial Intelligence (AI) in Oncology Market, by End-Users, 2023-2032
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Diagnostic Centers
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Pharmaceutical Companies
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Research Institutes
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Artificial Intelligence (AI) in Oncology Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Component (2020-2032)
12.1.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.1.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.1.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Component (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Component (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Component (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.5.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Component (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-Users (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Component (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Treatment Type (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-Users (2020-2032)
Chapter 13. Company Profiles
13.1. IBM
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Azra AI
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Siemens Healthineers
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. GE Healthcare
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Intel
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Path AI
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. NVIDIA
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Concert.AI
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Digital Diagnostics Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Median Technologies
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
